FDA/NCI DRUGS FOR CANCER PREVENTION "WHITE PAPER"
FDA/NCI DRUGS FOR CANCER PREVENTION "WHITE PAPER" should be completed by the end of the summer, FDA's Division of Oncology and Pulmonary Drugs forecasts. The white paper will focus on drugs for cancer prevention and will cover all phases of drug development. The guideline will detail procedures for studies in animals, toxicology and efficacy, as well as examine the design and endpoints for Phase I, Phase II and Phase III cancer prevention clinical trials.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth